Work

Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

Year: 2013

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-13-c295

Authors: Zev A. Wainberg, Johann S. de Bono, Lida Mina, Jasgit Sachdev, Lauren Averett Byers, Rashmi Chugh, Charlie Zhang, Joshua W. Henshaw, Andrew Dorr, John Glaspy, Ramesh Ramanathan

Institutions: University of California, Los Angeles, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Indiana University Indianapolis, Translational Genomics Research Institute, The University of Texas MD Anderson Cancer Center, University of Michigan

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2046389905

Cites:

Cited by: 11

Related to: 10